Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting
Rocaltrol® City Tour·Shanghai Station
On June 7, 2023, the first event of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was successfully held in Shanghai San Want Hotel. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.
The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and Zhang Zhenlin, the leader of the guideline writing group with profound academic attainments and the director of the Osteoporosis and Osteopathy Department of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, was invited The professor presided over the meeting, and three speakers with rich clinical experience introduced in detail the relevant content of diagnosis and treatment in the new version of the guidelines, and sorted out the important role of Rocaltrol in the field of osteoporosis. Experts in the field of osteoporosis communicated with each other and shared hot information on osteoporosis treatment, which fully reflected the purpose of the “city meeting” to build a communication platform for doctors and promote the linkage between doctors outside the hospital.
After the meeting started, Professor Zhang Zhenlin first thanked all the participants for attending the meeting in spite of their busy schedules, and also thanked Pharmanovia & Hesenna for their continuous attention to the field of osteoporosis treatment, and introduced the clinical development history of Rocaltrol. Then Dr. Li Shanshan, a specialist in Osteoporosis and Osteopathy from the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, was invited to introduce the diagnosis and differential diagnosis of osteoporosis to the participating experts. Through a large number of clinical cases, she shared her work in detail It also pointed out that the smart and compact dual-energy bone densitometer can bring convenience to the screening and diagnosis of osteoporosis, and provided new ideas for osteoporosis diagnosis to the participating experts.
The second topic of the meeting was taught by Professor Yue Hua, Deputy Director of Osteoporosis and Osteopathy Administration and Secretary of the Guideline Writing Group of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Professor Yue Hua conducted an in-depth discussion on the main drugs for the prevention and treatment of osteoporosis In the introduction, the role of active vitamin D (Rocaltrol) on bone density was specifically mentioned when supplementing the basic bone health supplement vitamin D in the basic measures. The bisphosphonate ibandronic acid (Bonviva) among bone resorption inhibitors is also the key to anti-osteoporosis treatment.
Finally, Professor Fu Peiliang, deputy director of joint surgery/orthopedics at the Second Affiliated Hospital of the Naval Military Medical University, combined with a large number of cases encountered in his surgical treatment, pointed out that active vitamin D (Rocaltrol) plays an important role in the quality of surgery, patient treatment and rehabilitation.
Professor Zhang Zhenlin presided over the final discussion session. Many experts discussed the problems encountered in their clinical practice. Finally, Professor Zhang Zhenlin hoped that Pharmanovia & Hesenna would speed up the introduction of monthly oral bisphosphonate tablets (Bonviva) for the Chinese osteoporosis patients bring good news.
